Collapse At SUMMIT: GSK Respiratory Trial Failure Is Major Setback
This article was originally published in Scrip
Executive Summary
The SUMMIT mortality trial conducted by GlaxoSmithKline plc and partner Theravance Inc. of their once-daily LABA/ICS therapy Relvar/Breo Ellipta (fluticasone furoate/vilanterol) in chronic obstructive pulmonary disease (COPD) has failed to meet its primary endpoint, initial data show.